Zhen Gao, Jing Wang, Jing Jing, Xu Dan, Zheng Li, Li Fengsen
National Clinical Research Base of Traditional Chinese Medicine, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi 830000, China.
Evid Based Complement Alternat Med. 2018 Jul 18;2018:7297141. doi: 10.1155/2018/7297141. eCollection 2018.
In China, the Chinese medicine formula modified zhisou powder (MZP) is commonly used to treat COPD with cold-dryness syndrome (CDSCOPD) to relieve cough and sputum. However, the underlying mechanisms of MZP on treating CDSCOPD remain to be elucidated. . COPD and CDSCOPD rat models were established; MZP was given to CDSCOPD rats in the last 7 days of the 97-day model establishment. Then the rats were subjected to lung function measurement. Pathological changes in lungs were observed through paraffin section and H&E staining. The mRNA and protein levels of AQP1, 4, and 5 and Muc5AC and Muc5B in lung were determined by quantitative RT-PCR and western blotting. NE levels was determined by ELISA. . The impaired lung functions were observed in rats exposed to cigarette smoke. Among all parameters evaluating lung functions, only tidal volume demonstrates a further decrease in CDSCOPD when compared with COPD, indicating further impaired pulmonary ventilation functions upon cold-dryness stimulation. The intervention of MZP effectively improved lung functions parameters, prevented the inflammations, and eliminated the increases of AQP4 and 5 and the decrease of Muc5AC in lung. MZP probably improves pulmonary functions in CDSCOPD through inhibiting lung inflammation, increasing expressions of AQPs, and decreasing Muc5AC expression in lung.
在中国，中药方剂止嗽散加减（MZP）常用于治疗慢性阻塞性肺疾病（COPD）寒燥证（CDSCOPD）以缓解咳嗽和咳痰。然而，MZP治疗CDSCOPD的潜在机制仍有待阐明。建立了COPD和CDSCOPD大鼠模型；在97天模型建立的最后7天给CDSCOPD大鼠给予MZP。然后对大鼠进行肺功能测量。通过石蜡切片和苏木精-伊红染色观察肺组织的病理变化。采用定量逆转录聚合酶链反应（qRT-PCR）和蛋白质免疫印迹法检测肺组织中AQP1、4、5以及Muc5AC和Muc5B的mRNA和蛋白水平。采用酶联免疫吸附测定法（ELISA）测定中性粒细胞弹性蛋白酶（NE）水平。暴露于香烟烟雾的大鼠出现肺功能受损。在所有评估肺功能的参数中，与COPD相比，仅潮气量在CDSCOPD中进一步降低，表明寒燥刺激后肺通气功能进一步受损。MZP干预有效改善了肺功能参数，预防了炎症反应，并消除了肺组织中AQP4和5的增加以及Muc5AC的减少。MZP可能通过抑制肺部炎症、增加水通道蛋白（AQPs）的表达以及降低肺组织中Muc5AC的表达来改善CDSCOPD的肺功能。
